Medicus Pharma (MDCX) is highlighted as a NASDAQ-listed emerging growth company with two lead assets, one in skin cancer and another in prostate cancer, poised at an inflection point.
Source Post
Potential Explosive Move Coming‼️Meet Dr. Raza Bokhari, CEO of Medicus Pharma (MDCX)
Jun 26, 2026
Chris Sain interviews Dr. Raza Bokhari, CEO of Medicus Pharma (MDCX), a NASDAQ-listed company focused on advancing novel therapeutic assets. The discussion highlights their lead assets in skin cancer and prostate cancer, emphasizing an upcoming inflection point for their skin cancer drug, SkinJet, which has completed Phase 2 trials and is preparing for a registrational study and potential partnership with larger players. The CEO expresses high confidence in the company's business model of acquiring and developing companies to position them for acquisition by larger entities.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.